Supreme Court agrees to hear Teva's Copaxone patent case

The Supreme Court will hear a case during its 2014-15 term, which starts in October, regarding Teva's patents on multiple sclerosis drug Copaxone. A reversal of a lower court's ruling would uphold the patents until September 2015, but competitors might introduce generic versions as early as next month. Experts say the case could have far-reaching effects on how patents are interpreted.

View Full Article in:

Bloomberg · New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA